Search

Zentalis Pharmaceuticals Inc

Lezárt

3.82

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

3.76

Maximum

3.9699999999999998

Fő mutatók

By Trading Economics

Bevétel

-42M

-78M

Egy részvényre jutó nyereség

-0.59

Munkavállalók

106

EBITDA

-42M

-77M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+131.15% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 6.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

20M

351M

Előző nyitás

3.82

Előző zárás

3.82

Zentalis Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 20. 23:56 UTC

Chubb Ltd shares are modestly higher in after-market trading. No specific company news was identified to explain this movement.

2026. aug. 20. 23:56 UTC

Centene Corp. shares are higher in after-market hours, recovering slightly following three consecutive lower sessions. No specific news has been identified.

2026. aug. 20. 23:56 UTC

Correlated Moves

Hancock Whitney Corp shares were little changed after hours, following a session where the Russell 2000 Index gained slightly. The stock has declined for six straight sessions.

2026. aug. 20. 23:56 UTC

Lexicon Pharmaceuticals Inc shares are rising in after-market trading, showing positive momentum despite being below their 20-day moving average. No specific news was identified.

2026. aug. 20. 23:56 UTC

Astronics Corp shares are higher in after-market hours, diverging from a broader market decline amid rising Treasury yields and geopolitical tensions.

2026. aug. 20. 23:56 UTC

Union Pacific Corp shares are higher in after-market trading, reflecting a recovery from earlier lows amid rising U.S. Treasury yields and oil prices.

2026. aug. 20. 23:56 UTC

Correlated Moves
ETF Constituents

iShares MSCI Canada ETF trades lower in after-market hours, impacted by negative returns from key holdings CNQ and KGC, despite positive USD/CAD movement.

2026. aug. 20. 23:56 UTC

Energy Recovery Inc's shares are higher in after-market hours, though no specific news was identified to explain the movement. The stock remains below its 20-day moving average.

2026. aug. 20. 23:56 UTC

Correlated Moves
News

The Vanguard Mortgage-Backed Securities ETF remains roughly flat in after-market trading amid rising yields and concerns over high borrowing costs and geopolitical risks.

2026. aug. 20. 23:56 UTC

Old National Bancorp shares are lower in after-market hours following a volatile session, amid rising U.S. Treasury yields and geopolitical tensions.

2026. aug. 20. 23:56 UTC

LyondellBasell Industries NV shares are trading higher in after-market hours. The move comes amid rising U.S. Treasury yields and geopolitical tensions.

2026. aug. 20. 23:56 UTC

Antero Resources Corp. experienced routine trading activity after market hours, remaining roughly flat. The stock is positioned above its 20-day moving average.

2026. aug. 20. 23:56 UTC

Correlated Moves

Synchrony Financial shares are higher in after-market trading, though they remain below their 20-day moving average after five consecutive lower daily closes.

2026. aug. 20. 23:56 UTC

Amplitude Inc shares are higher in after-market hours, though no specific news was identified. The stock has performed well since July 21.

2026. aug. 20. 23:56 UTC

Yeti Holdings Inc. shares traded roughly flat in after-market hours, remaining near the lower end of their one-month range amid a weaker performance backdrop.

2026. aug. 20. 23:56 UTC

DTE Energy Co. shares are lower in after-market trading, continuing a decline amid rising U.S. Treasury yields and increasing oil prices.

2026. aug. 20. 23:56 UTC

CoStar Group Inc shares are higher in after-market trading, remaining above their 20-day moving average despite no specific news identified.

2026. aug. 20. 23:56 UTC

Comstock Resources Inc. shares are trading higher in after-market hours, amid rising U.S. Treasury yields and increasing oil prices. No specific news was identified.

2026. aug. 20. 23:56 UTC

Immunovant Inc shares are lower in after-market trading, with no specific news identified. The stock remains above its 20-day moving average.

2026. aug. 20. 23:56 UTC

Aptiv PLC shares are trading higher in after-market hours, recovering from an initial dip. No specific news was identified to explain the movement.

2026. aug. 20. 23:56 UTC

Enovix Corp shares were roughly flat in after-market hours. The asset remains significantly lower compared to its performance over the past month.

2026. aug. 20. 23:56 UTC

American Express shares are trading higher in after-market hours, despite remaining below their 20-day moving average and near the lower end of their one-month range.

2026. aug. 20. 23:56 UTC

Allstate Corp shares traded roughly flat in after-market hours amid rising U.S. Treasury yields and ongoing geopolitical tensions related to U.S.-Iran relations.

2026. aug. 20. 23:56 UTC

Correlated Moves
Macro News
ETF Constituents

KOSPI rises significantly, bolstered by financial shares, while after-market trading shows gains for the Financial Select Sector SPDR Fund amid rising crude oil prices.

2026. aug. 20. 23:56 UTC

United States Oil Fund LP is trading lower in after-market hours, continuing a decline since Thursday's close amid mixed global equity performance.

2026. aug. 20. 23:56 UTC

Correlated Moves
Macro News
ETF Constituents

The iShares MSCI Japan ETF is higher in after-market trading, reflecting a rebound in the Japanese stock market despite negative USD/JPY impacts.

2026. aug. 20. 23:56 UTC

Social Media

Alibaba Group Holding Ltd shares are lower in after-market trading, currently at $130.29, facing resistance at $132 amid a recent decline in market sentiment.

2026. aug. 20. 23:56 UTC

ETF Constituents

OSIS led declines among Vanguard Information Technology ETF holdings, while the ETF traded little changed in after-market hours following mixed global equity performance.

2026. aug. 20. 23:56 UTC

Horace Mann Educators Corp shares are lower in after-market trading, continuing a decline since Thursday's close amid rising Treasury yields and geopolitical tensions.

2026. aug. 20. 23:56 UTC

Sarepta Therapeutics Inc. shares traded roughly flat in after-market hours, remaining above their 20-day moving average and near the upper end of their one-month range.

Társak összehasonlítása

Árváltozás

Zentalis Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

131.15% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 8.83 USD  131.15%

Magas 11 USD

Alacsony 5 USD

6 Wall Street elemző 12 hónapos célárain alapulva a(z)Zentalis Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

6 ratings

5

Vétel

1

Tartás

0

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat